Immunocore Holdings plc (IMCR): Price and Financial Metrics
IMCR Price/Volume Stats
|Current price||$53.13||52-week high||$67.43|
|Prev. close||$52.58||52-week low||$42.21|
|Day high||$53.95||Avg. volume||257,718|
|50-day MA||$48.36||Dividend yield||N/A|
|200-day MA||$54.89||Market Cap||2.60B|
IMCR Stock Price Chart Interactive Chart >
Immunocore Holdings plc (IMCR) Company Bio
Immunocore Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops and commercializes a new generation of transformative medicines to address unmet needs in cancer, infection, and autoimmune diseases. Immunocore Holdings serves customers in the United Kingdom and the United States.
IMCR Latest News Stream
|Loading, please wait...|
IMCR Latest Social Stream
View Full IMCR Social Stream
Latest IMCR News From Around the Web
Below are the latest news stories about IMMUNOCORE HOLDINGS PLC that investors may wish to consider to help them evaluate IMCR as an investment opportunity.
Bears are Losing Control Over Immunocore Holdings PLC Sponsored ADR (IMCR), Here's Why It's a 'Buy' Now
Immunocore Holdings PLC Sponsored ADR (IMCR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now. If you want to skip our overview of the British economy, then take a look at 5 Best Undervalued UK Stocks To Buy Now. The U.K. is one of the biggest economies in the world and a […]
Wall Street Analysts See a 66.42% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?
The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 66.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major markets with continued reimbursement expansion globally New Phase 3 clinical trial of KIMMTRAK adjuvant therapy for uveal (or ocular) melanoma (ATOM) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) Long-term survival for KIMMTRAK in metastatic uveal melanoma demonst
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, will present data for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma and cutaneous melanoma at the Society for Immunotherapy
IMCR Price Returns